Back

Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes

Ware, K. E.; Gupta, S.; Eng, J.; Kemeny, G.; Puviindran, B. J.; Foo, W.-C.; Crawford, L. A.; Almquist, R. G.; Runyambo, D.; Thomas, B. C.; Sheth, M. U.; Agarwal, A.; Pierobon, M.; Petricoin, E. F.; Corcoran, D. L.; Freedman, J.; Patierno, S. R.; Zhang, T.; Gregory, S.; Sychev, Z.; Drake, J. M.; Armstrong, A. J.; Somarelli, J.

2020-04-24 cancer biology
10.1101/2020.04.22.050385 bioRxiv
Show abstract

Adaptation of cancer cells to targeted therapy follows ecological paradigms observed in natural populations that encounter resource depletion and changing environments, including activation of pro-survival mechanisms, migration to new locations, and escape of predation. We identified the p38 MAPK pathway as a common molecular driver of these three responses during the adaptation to hormone therapy resistance in prostate cancer. The p38 pathway is activated in therapy-resistant cells and mechanistically drives these three convergent responses through sustained AR activity, enhanced invasion and metastasis, and immune evasion. Targeting p38 signaling may represent a new therapeutic strategy to treat men with metastatic, hormone therapy-resistant prostate cancer.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.